Dindolyl Methane, or DIM as it is commonly referred to, is a popular supplement for bodybuilders and others who are interested in increasing the size of their muscles. However there have been some recent studies that have linked health risks that DIM can cause. DIM can cause liver damage when taken in excess. A related risk is kidney damage, which can lead to kidney failure. Many bodybuilders and athletes are worried about the long-term health risks associated with DIM.
The majority of people take a diindolylmethane supplement to improve the production of testosterone. It is well-known that testosterone acts as an androgen. This means that it can cause hormone changes in the tissues. Research has shown DIM to mimic the effects both of testosterone and other hormones. Since men produce more testosterone than women do, some manufacturers have added diindolylmethane into their products in order to make them more competitive in male circles. Men will respond to products that mimic testosterone naturally.
As a result, many companies advertise DIM as a cancer-fighter. Although diindolylmethane is effective in reducing the growth of tumors in laboratory animals, it was given orally to the animals. To achieve the same effect diindolylmethane needs to be taken in large doses over a long time. The animals that were examined did not show indications of cancer for a number of years. However, they all developed liver disease after drinking excessive amounts of diindolylmethane. For a thorough look at the way DIM is affecting the body, you should seek out a medical professional.
According to the US National Institute of Environmental Health Safety and Security, the only way to demonstrate that DIM is effective in treating breast cancer is to conduct an experiment where cells from healthy breast cancer cells are exposed to large doses of diindolylmethane for a long period of time. There are pros and cons to using DIM as with any chemical. The advantages include the ability to mimic hormones. This allows you to make insulin that can stop cancer cell growth. The disadvantages are that diindolylmethane can also produce a potentially damaging chemical known as DMSO. Read more about diindolylmethane dim here.
One of the most commonly used claims for diindolylmethane’s use as treatment for various illnesses is that it functions as an natural, antibacterial, anti-cancer, and anti-fungal agent. The National Institute of Health, in their exhaustive study of supporting data, concluded that there was no basis for these claims. According to the Institute of Chemical Technology, there was no research conducted to support this claim. The Institute of Chemical Safety, through an in-depth examination of the safety profile of the firestone concluded that the information presented by pharmaceutical companies about the benefits of diindolylmethane for humans were not entirely reliable.
In a May 2021 edition of the Journal of Toxicology and Environmental Health, van der Goes, et al. Van der Goes, and., highlighted the potential dangers of diindolylmethane usage, which include allergic reactions and skin rashes, asthma attacks as also headaches, dizziness and respiratory problems. The daily dose recommended for this chemical, which is approximately one tenth to a teaspoon was 0.2 milligrams. It is not clear what the concentration is when compounded with other substances. Since this substance hasn’t been thoroughly examined, it isn’t considered safe at any point.
The view abstract indicates that the use of diindolylmethane (DIEM) in the treatment of cancer is based on the principle of inhibiting intracellular inhibition of pyruvate metabolite through flavenoids, thereby hindering the accumulation of oxalates in renal tubule cells as well as adenine granulocyte cultures. The toxicology studies of the drug metabiplicate have not demonstrated that this chemical could cause overdose. The Food and Drug Administration approved this substance as a prescribed drug in June 1996. According to the FDA the manufacturer of firestone tincture is currently in the process of completing two major clinical trials – one in Europe and the other in the United States.
The view abstract also shows that diindolylmethane’s use in cancer treatment is based on the concept of inhibiting intracellular inhibition through flavenoids of pyruvate metabolism , and thus stopping the accumulation of adenine and oxalates in renal tubule cells. However, the drug metabiplicate toxicology studies did not provide evidence convincing that consumption of this chemical causes an overdose. In June 1996, the Food and Drug Administration approved this drug as a prescribed drug. According to the FDA the manufacturer of firestone tincture is in process of completing two major trials–one in Europe and one in the United States. According to the FDA the company that produces firestone tincture is in process of conducting two major trials in Europe and one in the United States.